Summary:
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
Qualified Participants Must:
Be between 18 and 70 years or age
Be diagnosed with schizophrenia
Qualified Participants May Receive:
study-related medical care and investigational medication at no cost and may be compensated for time and travel.